Gennao Bio Expands Leadership Team with Two Key Appointments

– Joseph W. McIntosh, M.D., Joins as Chief Medical Officer –

– Anuj Goswami, J.D., MBA, Joins as General Counsel –

HOPEWELL, N.J., January 6, 2022 — Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointments of Joseph W. McIntosh, M.D., as chief medical officer, and Anuj Goswami, J.D., MBA, as general counsel.

“We are thrilled to welcome Joe and Anuj to the Gennao Bio team. Joe is a proven leader with significant expertise in rare disease and oncology drug development and Anuj has deep legal experience leading financing and M&A transactions, as well as corporate governance, IP, and compliance activities for life science companies,” said Stephen Squinto, Ph.D., chief executive officer and chair of the board of Gennao Bio. “These appointments reflect the tremendous growth of our organization, and our dedication to bringing together a best-in-class team to develop our GMAB platform for oncology and rare monogenic skeletal muscle diseases.”

Dr. McIntosh joins Gennao with more than 16 years of drug development experience in the biopharmaceutical industry, with a focus on gene therapies and rare genetic disease. Previously, he served as chief medical officer for Jaguar Gene Therapy, responsible for the development of the company’s AAV9-based gene therapies. Prior to Jaguar, he served as chief medical officer at Aruvant Sciences, overseeing the clinical development of the company’s investigational gene therapy for sickle cell disease. Earlier in his career, he held positions of increasing leadership at PTC Therapeutics, NPS Pharmaceuticals, Eisai and Pfizer. Before joining the biopharma industry, he trained in emergency medicine at Kent and Canterbury Hospital in the UK. Dr. McIntosh earned a bachelor’s degree in chemistry and biochemistry and a medical degree from the University of Witwatersrand in South Africa.

Mr. Goswami joins the Gennao team with over 20 years of experience in private practice at Ballard Spahr LLP in Philadelphia. As a partner in Ballard’s Business & Finance practice, he served numerous clients through various stages of the growth cycle, leading multi-disciplinary teams to support a range of early stage and public company clients. Mr. Goswami brings a breadth of expertise advising clients in the life sciences, technology, and retail sectors on a variety of matters, including equity and debt financing, corporate governance, M&A transactions and employment law. He received his B.A. in economics from Haverford College and his J.D. and MBA from The Ohio State University.

About Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.